Answers are grounded in this paper and cite their sources.
Literature review demonstrates efficacy and safety of second-line treatment for erectile dysfunction post-radical prostatectomy, highlighting patient outcomes and compliance.
Erectile dysfunction (ED) is a frequent and significant complication of radical prostatectomy that impacts patients’ quality of life. Intracavernous injection treatment has become an important approach to post-prostatectomy ED, providing an immediate and proven means of regaining erectile function in men who are unresponsive to oral phosphodiesterase type 5 inhibitors. The scope of this article is to discuss the mechanisms, efficacy, and safety of ICI treatments using vasoactive compounds as a second-line treatment for ED after radical prostatectomy. We consider clinical results, satisfaction, and compliance, as well as predictors of success, like nerve-sparing procedures. Through our interpretation of evidence and clinical experience, ICI therapy is a cornerstone of penile rehabilitation and ED management following radical prostatectomy. Also, the prospects for further treatment optimization and patient outcomes are discussed.
No takes yet. Share an insight, caveat, or question.
Vlaicu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: